Eli Lilly将建造6.5B休斯顿工厂, 用于减重药物或假药, 创造615个就业机会。 Eli Lilly to build $6.5B Houston plant for weight-loss drug orforglipron, creating 615 jobs.

Eli Lilly将在休斯敦建造一个65亿美元的制造厂,为口服减重药物或其他先进疗法生产活性成份,创造615个长期就业机会和4 000个建筑工作。 Eli Lilly will build a $6.5 billion manufacturing plant in Houston to produce active ingredients for its oral weight-loss drug orforglipron and other advanced therapies, creating 615 permanent jobs and 4,000 construction jobs. 该设施预计将在五年内开放,是范围更广的270亿美元的美国扩大计划的一部分,计划建造4个新地点。 The facility, expected to open within five years, is part of a broader $27 billion U.S. expansion plan, with four new sites planned. Orforglipron,GLP-1受体激动剂,定于年底提交管制性文件,最高销售额可达250亿美元。 Orforglipron, a GLP-1 receptor agonist, is set for regulatory submission by year-end and could reach $25 billion in peak sales. 这一举动支持了美国在制造业投资增加和贸易政策改变的情况下对GLP-1型药物日益增长的需求。 The move supports growing U.S. demand for GLP-1 drugs amid increased manufacturing investment and shifting trade policies.